SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity
Authors:
- Ninaad LasradoNLNinaad Lasrado
- Katherine McMahanKMKatherine McMahan
- Nicole P. HachmannNHNicole P. Hachmann
- Catherine Jacob-DolanCJCatherine Jacob-Dolan
- Jinyan LiuJLJinyan Liu
- Kristin A. GotthardtKGKristin A. Gotthardt
- Darren M. TyDTDarren M. Ty
- Juliana PereiraJPJuliana Pereira
- Camille R. MazurekCMCamille R. Mazurek
- 23 October 2024
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (770) , eadp8920
Abstract
Current COVID-19 vaccines provide robust protection against severe disease but minimal protection against acquisition of infection. Intramuscularly administered COVID-19 vaccines induce robust serum neutralizing antibodies (NAbs), but their ability to boost mucosal immune responses remains to be determined. In this study, we show that the XBB.1.5 messenger RNA (mRNA) boosters result in increased serum neutralization to multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in humans, including the dominant circulating variant JN.1. In contrast, we found that the XBB.1.5 mRNA booster did not augment mucosal NAbs or mucosal IgA responses, although acute SARS-CoV-2 XBB infection substantially increased mucosal antibody responses. These data demonstrate that current XBB.1.5 mRNA boosters substantially enhance peripheral antibody responses but do not robustly increase mucosal antibody responses. Our data highlight a separation between the peripheral and mucosal immune systems in humans and emphasize the importance of developing next-generation vaccines to augment mucosal immunity to protect against respiratory virus infections.Keywords
This publication has 46 references indexed in Scilit:
- Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA VaccinationJAMA Network Open, 2024
- Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunityMucosal Immunology, 2024
- SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responsesEBioMedicine, 2023
- SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodiesJournal of Allergy and Clinical Immunology: Global, 2023
- Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8+ T cell responses post SARS-CoV-2 infectionImmunity, 2023
- Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccinationImmunity, 2021
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed IndividualsCell, 2020
- Induction of secretory immunity and memory at mucosal surfacesVaccine, 2007
- IgG transport across mucosal barriers by neonatal Fc receptor for IgG and mucosal immunitySpringer Seminars in Immunopathology, 2006
- Human Neonatal Fc Receptor Mediates Transport of IgG into Luminal Secretions for Delivery of Antigens to Mucosal Dendritic CellsImmunity, 2004